W
William G. Hawkins
Researcher at Washington University in St. Louis
Publications - 258
Citations - 14987
William G. Hawkins is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 57, co-authored 221 publications receiving 11606 citations. Previous affiliations of William G. Hawkins include University of North Carolina at Chapel Hill & Barnes-Jewish Hospital.
Papers
More filters
Journal ArticleDOI
Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology
Margaret A. Tempero,Mokenge P. Malafa,Mahmoud M. Al-Hawary,Horacio J. Asbun,Andrew Bain,Stephen W. Behrman,Al B. Benson,Ellen F. Binder,Dana Backlund Cardin,Charles Cha,E. Gabriela Chiorean,Vincent Chung,Brian G. Czito,Mary Dillhoff,Efrat Dotan,Cristina R. Ferrone,Jeffrey M. Hardacre,William G. Hawkins,Joseph M. Herman,Andrew H. Ko,Srinadh Komanduri,Albert C. Koong,Noelle K. LoConte,Andrew M. Lowy,Cassadie Moravek,Eric K. Nakakura,Eileen M. O'Reilly,Jorge Obando,Sushanth Reddy,Courtney L. Scaife,Sarah P. Thayer,Colin D. Weekes,Robert A. Wolff,Brian M. Wolpin,Jennifer L. Burns,Susan Darlow +35 more
TL;DR: The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection, as well as on management of locally advanced unresectable and metastatic disease.
Journal ArticleDOI
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang,Samarth Hegde,Brett L. Knolhoff,Yu Zhu,John M. Herndon,Melissa A. Meyer,Timothy M. Nywening,William G. Hawkins,Irina M. Shapiro,David T. Weaver,Jonathan A. Pachter,Andrea Wang-Gillam,David G. DeNardo +12 more
TL;DR: It is suggested that FAK inhibition increases immune surveillance by overcoming the fibrotic and immunosuppressive PDAC TME and renders tumors responsive to immunotherapy.
Journal ArticleDOI
The accordion severity grading system of surgical complications.
TL;DR: Current methods for reporting the severity of complications incompletely fulfill the needs of authors of surgical studies and a new system—the Accordion Severity Grading System—is presented.
Journal ArticleDOI
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening,Andrea Wang-Gillam,Dominic E. Sanford,Brian A. Belt,Roheena Z. Panni,Brian Cusworth,Adetunji T. Toriola,Rebecca Nieman,Lori A. Worley,Motoyo Yano,Kathryn J. Fowler,A. Craig Lockhart,Rama Suresh,Benjamin R. Tan,Kian-Huat Lim,Ryan C. Fields,Steven M. Strasberg,William G. Hawkins,David G. DeNardo,S. Peter Goedegebuure,David C. Linehan +20 more
TL;DR: This trial aimed to establish the safety, tolerability, and recommended phase 2 oral dose of the CCR2 inhibitor PF-04136309 in combination with FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil) and analysed the primary outcome by intention to treat.
Journal ArticleDOI
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression
Yu Zhu,John M. Herndon,Dorothy K. Sojka,Ki-Wook Kim,Brett L. Knolhoff,Chong Zuo,Darren R. Cullinan,Jingqin Luo,Audrey R. Bearden,Kory J. Lavine,Wayne M. Yokoyama,William G. Hawkins,Ryan C. Fields,Gwendalyn J. Randolph,David G. DeNardo +14 more
TL;DR: Unexpectedly, significant portions of pancreas‐resident macrophages originated from embryonic development and expanded through in situ proliferation during tumor progression and demonstrate a unique pro‐fibrotic transcriptional profile distinct from that of their monocyte‐derived counterparts.